2
TUESDAY, NOVEMBER 23, 1003
TO
IN 1991 THE BUILDING AUTHORITY ANNOUNCED ITS POLICY PROSECUTE OWNERS WHO CARRY OUT BUILDING WORKS WITHOUT APPROVAL OR WHO FAIL TO COMPLY WITH REMOVAL ORDERS.
ΤΟ
DATE THERE HAVE BEEN 275 SUCCESSFUL PROSECUTIONS, RESULTING IN A TOTAL OF MORE THAN $1.6 MILLION IN FINES IMPOSED BY THE COURTS.
IN
THEIR UBW.
THESE CASES, CONVICTED OWNERS ARE STILL REQUIRED TO REMOVE
IN THE SAME YEAR THE AUTHORITY LAUNCHED A CAMPAIGN, CALLED OPERATION APPENDAGES, TO REMOVE UNAUTHORISED STRUCTURES ON A BUILDING- BY-BUILDING BASIS.
THIS WAS FOLLOWED BY OPERATION CATHERINE WHEEL ROLLING STONE EARLIER THIS YEAR.
AND OPERATION
IN THE FIRST THREE QUARTERS OF THIS YEAR OVER 5,000 REMOVAL ORDERS WERE SERVED THROUGHOUT THE URBAN AREAS. IT WAS FOUND THAT, ON A DISTRICT BOARD BOUNDARY BASIS, AS MUCH AS 75 PER CENT OF THE ORDERS WERE SERVED ON PREMISES ENJOYING A MORTGAGE.
ORDERS
LAST YEAR THE BUILDING AUTHORITY ISSUED MORE THAN 6,750 IN RESPECT OF UBW. IT IS EXPECTED THAT A SIMILAR NUMBER OF ORDERS WILL BE ISSUED THIS YEAR.
—
DEVELOPMENTS OF PHARMACEUTICAL INDUSTRY IN HK
HONG KONG IS AN IDEAL LOCATION FOR IMPORTERS OF PHARMACEUTICAL PRODUCTS SERVING THE GROWING CHINA MARKET AND OTHER PARTS OF ASIA, THE FINANCIAL SECRETARY, MR HAMISH MACLEOD, SAID TODAY (TUESDAY).
HE
WAS SPEAKING AT THE SILVER JUBILEE YEAR DINNER OF THE HONG KONG ASSOCIATION OF THE PHARMACEUTICAL INDUSTRY.
HE NOTED THAT IMPORTS OF PHARMACEUTICAL PRODUCTS HAD TRIPLED SINCE THE MID-1980S, AND WERE WORTH $7,577 MILLION LAST YEAR.
"OVER THE SAME PERIOD, RE-EXPORTS ALSO QUADRUPLED, RISING TO $5,711 MILLION BY 1992. MOST OF THE RE-EXPORTS WENT TO CHINA, HE SAID,
HE ADDED THAT HONG KONG ALSO OFFERED OPPORTUNITIES TO DEVELOP PHARMACEUTICAL PRODUCTS SPECIALLY TARGETED AT ASIA MARKETS.
FOR EXAMPLE, HE SAID, A U.S. COMPANY FORMED A JOINT VENTURE WITH THE HONG KONG INSTITUTE OF BIOTECHNOLOGY IN EARLY 1991 TO DEVELOP HERBAL EXTRACTS PROVIDED BY CHINESE RESEARCH LABORATORIES INTO NEW PRODUCTS.
HE
ALSO POINTED OUT THAT ALTHOUGH HISTORICALLY HONG KONG HAD NOT BEEN A MAJOR EXPORTER OF PHARMACEUTICAL PRODUCTS ΤΟ THE WEST. THERE WAS A CHANGE RECENTLY.
HE NOTED THAT EARLIER
THIS YEAR, THE HONG KONG INDUSTRIAL ESTATES CORPORATION APPROVED AN APPLICATION FOR LAND FOR A PHARMACEUTICAL COMPANY TO BUILD A STAND-ALONE MANUFACTURING PLANT IN THE NEW TSEUNG KWAN O INDUSTRIAL ESTATE.
/"THE COMPANY